US20070149617A1 - Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs - Google Patents
Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs Download PDFInfo
- Publication number
- US20070149617A1 US20070149617A1 US11/558,568 US55856806A US2007149617A1 US 20070149617 A1 US20070149617 A1 US 20070149617A1 US 55856806 A US55856806 A US 55856806A US 2007149617 A1 US2007149617 A1 US 2007149617A1
- Authority
- US
- United States
- Prior art keywords
- omega
- lipid
- oil
- based emulsion
- hypoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 114
- 239000000839 emulsion Substances 0.000 title claims abstract description 81
- 150000002632 lipids Chemical class 0.000 title claims abstract description 62
- 210000000056 organ Anatomy 0.000 title claims abstract description 9
- 230000004224 protection Effects 0.000 title claims description 10
- 208000037906 ischaemic injury Diseases 0.000 title description 2
- 238000011084 recovery Methods 0.000 title 1
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 58
- 208000028867 ischemia Diseases 0.000 claims abstract description 45
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 30
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 30
- 230000030833 cell death Effects 0.000 claims abstract description 29
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 20
- 229930195729 fatty acid Natural products 0.000 claims abstract description 20
- 239000000194 fatty acid Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 17
- -1 DHA fatty acids Chemical class 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000926 neurological effect Effects 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 15
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 11
- 230000000302 ischemic effect Effects 0.000 abstract description 10
- 235000021323 fish oil Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 34
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 15
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 15
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 15
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 15
- 229940012843 omega-3 fatty acid Drugs 0.000 description 15
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229940090949 docosahexaenoic acid Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 239000002960 lipid emulsion Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000000451 tissue damage Effects 0.000 description 6
- 231100000827 tissue damage Toxicity 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 3
- 201000008247 brain infarction Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- CPWCKGMTKBLVHZ-UHFFFAOYSA-M 1,2,5-triphenyltetrazol-1-ium;chloride Chemical compound [Cl-].C1=CC=CC=C1C1=[N+](C=2C=CC=CC=2)N(C=2C=CC=CC=2)N=N1 CPWCKGMTKBLVHZ-UHFFFAOYSA-M 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 2
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003975 mesenteric artery Anatomy 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- NNVNAJGCZFCILW-UHFFFAOYSA-N 1'-methylspiro[3,4-dihydrochromene-2,4'-piperidine]-4-amine;hydrochloride Chemical compound Cl.C1CN(C)CCC21OC1=CC=CC=C1C(N)C2 NNVNAJGCZFCILW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 1
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100037314 Protein kinase C gamma type Human genes 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091006298 SLC2A3 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102100022722 Solute carrier family 2, facilitated glucose transporter member 3 Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 210000004462 astrocytic glia Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000006592 excitoxicity Effects 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009219 proapoptotic pathway Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Cerebral hypoxia-ischemia is a major cause of morbidity and mortality through all stages of the life cycle, including for infants born prematurely, for children in intensive care units, and for elderly with cerebral vascular accidents. Infants and children who survive hypoxic-ischemic encephalopathy demonstrate lifelong neurologic handicaps, including cerebral palsy, mental retardation, epilepsy, and learning disabilities. Vannucci, R. C. (2000). “Hypoxic-ischemic encephalopathy,” American Journal of Perinatology 17(3): 113-120.
- Lipid emulsions are commonly used in pediatric intensive care and are an important source of calories in these critically-ill children.
- Most commercially available emulsions are formed from soybean oil, which have high concentrations of omega-6 (n-6) fatty acids.
- Lipid emulsions rich in omega-3 (n-3) fatty acids such as ⁇ -linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are derived from fish oils, and are not yet widely available for clinical use.
- omega-3 oils have been shown to have beneficial effects in neurologic diseases such as epilepsy, depression, and behavioral disorders.
- the present invention provides a method of limiting neurological damage resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection against neurological damage.
- the present invention also provides a method of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection to limit cell death.
- Administration of the omega-3 lipid-based emulsion may be either enteral or parenteral. Methods of the present invention also provide further comprise administering a conventional stroke treatment or preventative medication.
- Omega-3 lipid-based emulsions of the present invention comprise at least 10%, preferably at least 20%, omega-3 oil, by weight.
- the omega-3 oil comprises at least 10%, preferably at least 20%, omega-3 triglyceride and/or omega-3 diglyceride and the fatty acids of the omega 3-triglyceride and/or omega-3 diglyceride comprise at least 40% EPA and/or DHA.
- Omega-3 lipid-based emulsions may be administered at any effective dose, such as a dose of 0.05 g/kg to 4 g/kg, and may be administered any time after a hypoxic-ischemic insult, such as 20 minutes to six hours after the ischemic insult or 0-12 hours after the ischemic insult. Additional later administrations are also contemplated, for example an additional later administration is provided 1-24 hours after the insult.
- the methods of the present invention are useful when ischemia has occurred in the organs selected from the group consisting of brain, lung, heart, kidney and large or small intestine.
- the present invention also provides an omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emusion confers a protective benefit on cells against cell death following a hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 triglyceride and/or diglycerides comprise at least 40% EPA and/or DHA.
- the present invention also provides the use of an omega-3 lipid-based emulsion as described herein to make a medicament to limit neurological damage and/or cell death resulting from hypoxic-ischemia.
- FIG. 1 provides the results of an experiment where rats were given an omega-3 lipid-based emulsion as a neuroprotective both prior and after 60 minutes of hypoxic-ischemia.
- FIG. 2 provides the results of an experiment where rats were given an omega-3 lipid-based emulsion as a neuroprotective both prior and after 65 minutes of hypoxic-ischemia.
- FIG. 3 shows the neuroprotective effect of omega-3 triglycerides just before hypoxic/ischemic insult on the size of brain infarcts as determined by TTC staining.
- FIG. 4 shows the results of four separate experiments where rats were given an omega-3 lipid-based emulsion after 60 minutes of hypoxic-ischemia. Note that 40% of the treated animals had no brain damage and another 40% had less damage than the mean of control animals as assessed by TTC staining.
- omega-3 lipid-based emulsion is an oil-in-water emulsion comprising at least about 10% omega-3 oil (and up to 100% omega-3 oil).
- omega-3 lipid-based emulsion comprises at least 20% omega-3 oil.
- omega-3 oils means any omega-3 fatty acid, including free omega-3 fatty acids and omega-3 triglycerides and omega-3 diglycerides.
- omega-3 fatty acid means a polyunsaturated fatty acid wherein one of the carbon-carbon double bonds is between the third and fourth carbon atoms from the distal end of the hydrocarbon side chain of the fatty acid.
- examples of “omega-3 fatty acid” include ⁇ -linolenic acid (18:3n-3; ⁇ -ALA; ⁇ 3,6,9 ), eicosapentaenoic acid (20:5n-3; EPA; ⁇ 5,8,11,14,17 ), docosahexaenoic acid (22:6n-3; DHA) and docosapentaenoic acid (22:5n-3; DPA; ⁇ 7,10,13,16,19 ), wherein EPA and DHA are most preferred.
- Omega-3 fatty acids having at least 20 carbon atoms are herein called “long chain omega-3 fatty acids.”
- omega-3 triglyceride or “omega-3 diglyceride” refers to a triglyceride or a diglyceride, respectively, comprising at least one omega-3 fatty acid esterified with a glycerol moiety.
- omega-3 tri/diglyceride means that omega-3 fatty acid comprises an omega-3 triglyceride and/or a diglyceride or any combination thereof.
- cerebral hypoxia-ischemia of sufficient duration to deplete high energy reserves in neural cells initiates a cascade of events over the hours to days of reperfusion that culminates in extensive death, both necrotic and apoptotic. These events include the generation of reactive oxygen species and oxidative damage to cells, release of inflammatory mediators and initiation of prolonged inflammatory reactions, and ongoing apoptosis that can continue for weeks to months. This applies to ischemic injury to organs in young, adult and elderly humans.
- neuronal loss following hypoxia/ischemia is believed to result, at least in part, from elevated glutamate release and excitoxicity.
- Excess glutamate activation of N-methyl-D-aspartic acid (NMDA) receptors induces pro-apoptotic pathways and inhibits anti-apoptotic signaling pathways.
- Omega-3 fatty acids can modify a number of signaling pathways to effect transcriptional regulation.
- omega-3 fatty acids protect neurons by modulating signaling pathways that counter the effects of hyper stimulated NMDA receptors, protection against free radical generation and consequent oxidative damage, and thereby prevent/reduce post-ischemic inflammation and release of inflammatory mediators.
- the present invention provides methods of limiting or preventing cell death and cell/tissue damage resulting from hypoxic-ischemia. “Limiting” as used herein includes decreasing and/or preventing.
- the methods of present invention comprise administering an omega-3 lipid-based emulsion of the present invention after an hypoxic-ischemia insult.
- the present invention also provides, in those cases where the hypoxic-ischemic insult can be predicted, methods of limiting or preventing cell death and cell/tissue damage comprising administering an omega-3 lipid-based emulsion of the present invention before the hypoxic-ischemia insult.
- the present invention limits neural cell death and/or limits neurological damage. Since the basic mechanisms of cell death following ischemia after an hypoxic-ischemic insult are similar in most bodily organs, the present invention also provides limiting cell death in other organs such as the heart, large and small intestines, kidney and lung following an hypoxic-ischemia insult. For example, after a colonic ischemic event due to acute mesenteric artery ischemia, chronic mesenteric artery ischemia or ischemia due to mesenteric venous thrombosis, the present invention provides a method of limiting intestinal cell death. Similar prevention of cell death would apply to myocardial infarction.
- omega-6 fatty acids such as omega-6 linoleic acids are far less effective in neuroprotection and cardiac protection when provided before an ischemic event.
- the studies involved the administration of Intralipid®, a soy oil based emulsion containing 55% of its fatty acids as omega-6 linoleic acid, with a very low content of EPA and DHA ( ⁇ 2%).
- Intralipid® a soy oil based emulsion containing 55% of its fatty acids as omega-6 linoleic acid
- DHA very low content of EPA and DHA
- the methods of the present invention comprise administering an omega-3 lipid-based emulsion comprising at least 10%, preferably at least 20% (up to 100%) by weight of omega-3 oil.
- the omega-3 oil comprises at least 10%, preferably at least 20% (up to 100%) omega-3 tri/diglycerides.
- the fatty acids in the omega-3 tri/diglycerides preferably comprise at least 40% (up to 100%) EPA and/or DHA.
- Sources of omega-3 fatty acids may be from any suitable source such as from fish oils, other oils or may even be synthesized. Although EPA and DHA are preferred omega-3 fatty acids, other omega-3 fatty acids may be used.
- Methods of the present invention preferably comprise administering omega-3 lipid-based emulsions of the present invention either enterally (for example, orogastric or nasogastric) or parenterally (for example, subcutaneous, intravenous, intramuscular, intraperitoneal). Most preferably the emulsion is administered intravenously.
- Omega-3 lipid-based emulsions of the present invention are preferably provided at a dose capable of providing a protective benefit.
- a suitable effective and tolerable dose for a human would be about 0.05 g/kg to about 4.0 g/kg. Higher doses may be given as necessary.
- Omega-3 lipid-based emulsions of the present invention are preferably administered parenterally and/or enterally after the ischemic insult (or in some embodiments, before the insult when it can be predicted).
- the emulsion may be administered to prevent/reduce tissue damage after cerebral hypoxia or stroke as well as hypoxic-ischemic insults in other organs such as heart, kidney, lung, etc.
- an omega-3 lipid-based emulsion is administered as soon as possible after the insult (or before in cases where the insult can be predicted) to provide a greater limitation of cell death.
- an omega-3 lipid-based emulsion is administered from 0-12 hours after the insult. Ideally the administration occurs anywhere from 20 minutes to 6 hours after the insult.
- the emulsion is administered 0-2 hours after the insult.
- the present invention also provides for multiple administrations of the omega-3 lipid-based emulsion.
- the emulsion may be first administered within 20 minutes of the insult, followed by a second administration 1-24 hours after the insult.
- the present invention also contemplates multiple administration(s) of omega-3 lipid-based emulsions following the insult.
- methods of limiting or preventing cell death and cell/tissue damage resulting from hypoxic-ischemia further comprise administering an omega-3 lipid-based emulsion of the present in conjunction with standard available therapies (such as surgery and angioplasty) and/or medications given to prevent or treat hypoxia-ischemia.
- therapies such as surgery and angioplasty
- the following drugs are often administered to prevent or treat strokes: antiplatelet medications such as aspirin, clopidogrel, dipyridamole, ticlopidine; anticoagulants such as heparin and warfarin; and thrombolytic agents such as tissue plasminogen activator.
- Omega-3 lipid-based emulsions may be oil-in-water (o/w) emulsions in which the outer continuous phase consists of distilled water purified or sterilized for parenteral purposes.
- oil-in-water emulsions may be obtained by standard methods, i.e. by mixing the oil components followed by emulsification and sterilization.
- the pH value of the lipid emulsion may be adjusted to a physiologically acceptable value, preferably to a pH of from about 6.0 to about 9.0, more preferably from about 6.5 to about 8.5.
- Auxiliary agents and additives may be added to the oil mixture prior to emulsification or prior to sterilization.
- Omega-3 lipid-based emulsions according to the invention can be prepared by known standard procedures with inertization. Typically, first the lipids, emulsifier and other auxiliary agents and additives are mixed and then filled up with water with dispersing. The water may optionally contain additional water-soluble components (e.g. glycerol). Preferably omega-3 lipid-based emulsions of the present invention contain lipid particles having a diameter of about 100-400 nanometer, with an average size of 300 nanometers.
- Omega-3 lipid-based emulsions of the present invention comprise at least 10%, preferably at least 20% (up to 100%) by weight of omega-3 oil.
- the omega-3 oil comprises at least 10%, preferably at least 20% (up to 100%) omega-3 tri/diglyceride.
- Fatty acids in the omega-3 tri/diglyceride preferably comprise at least 40% (up to 100%) EPA and/or DHA.
- the omega-3 lipid-based emulsion preferably comprises 10% to 100% omega-3 tri/diglyceride.
- omega-3 tri/diglyceride contains at least 40% (up to 100%) of their fatty acids as EPA and/or DHA.
- omega-3 emulsions of the present invention are sterile and have a particle size that is preferably between 100-400 nanometer mean diameter, with an average size of 300 nm.
- omega-3 lipid-based emulsion (0.25 cc)(a 20% long chain omega-3 triglyceride-based formula having >45% of total omega-3 fatty acid as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) via orogastric feeding tube, and six control rats were given 0.25 cc water, both enterally.
- the 20% omega-3 lipid-based emulsion was made placing 20 gm of omega-3 triglyceride in 100 ml of water, and emulsifying with 1.2 gm of egg yolk lecithin.
- Rats were allowed to recover for 2 hours, then they underwent hypoxia-ischemia for 60 minutes of 8% oxygen at a constant temperature.
- the six pre-treated rats were given another dose of 50 mg omega-3 lipid-based emulsion immediately after the hypoxia-ischemia and control rats were given another 0.25 cc water. All rats were euthanized at 72 hours of reperfusion.
- the brains were removed and cut into 2 mm sections and stained with 2,3,5,Triphenyl-2H-tetrazolium chloride (TTC).
- TTC 2,3,5,Triphenyl-2H-tetrazolium chloride
- the six pre-treated rats were given another dose of 50 mg omega-3 lipid-based emulsion immediately after the hypoxia-ischemia and control rats were given another 0.25 cc water. All rats were euthanized at 72 hours of reperfusion.
- the brains were removed and cut into 2 mm sections and stained with 2,3,5,Triphenyl-2H-tetrazolium chloride (TTC). The sections were scored as follows:
- Four of the six control rats survived with a mean score of 2.75+/ ⁇ 0.50, while five of the six treated rats survived with a mean score of 1.70+/ 0.76 (p ⁇ 0.05). See FIG. 2 .
- the rats were euthanized and their brains removed, cut into 2 mm sections and stained with 2,3,5triphenyl-2H-tetrazolium chloride (TTC).
- TTC 2,3,5triphenyl-2H-tetrazolium chloride
- the damage in each animal was then given a score from 0 (no damage) to 4 (>60% ipsilateral hemisphere infarcted).
- rat pups Postnatal day 19-21 rat pups were subjected to unilateral carotid artery ligation and 60 minutes of hypoxic ischemia, according to the previously described protocol.
- rats were treated by parenteral injection of omega-3 lipid-based emulsion (100 mg) immediately after the insult, and again at four hours after the insult.
- the emulsion was as described above in Example 1. Brain damage was evaluated by TTC staining at 72 hours of reperfusion. In each instance, administration of the omega-3 lipid-based oil emulsion provided greater than 50% protection, i.e. reduction of tissue damage.
- FIG. 4 shows the results of these experiments.
- FIG. 4 represents at total of 14 control subjects (saline-treated) and 21 treated subjects (omega-3 lipid-based emulsion treated). Mean damage scores were: 1.93 ⁇ 0.22 (SEM), control, 0.78 ⁇ 0.16 emulsion-treated; p ⁇ 0.0001 by two-tailed test.
- the data in FIG. 4 is presented as a scatter plot.
- 40% of the treated animals were 100% protected (no damage at all, compared to 1/14 untreated; 40% suffered only mild damage, compared to 1/14 mildly damaged untreated animals.
- Fatty acyl composition analyses of brain lipids (by gas liquid chromatography) after hypoxia/ischemia show no relative differences between infarcted brain versus non infarcted brain indicating that effects of acute administration of n-3 emulsions are not dependent on fatty acid compositional changes in brain membranes.
- absolute concentrations of all fatty acids fell to similar degrees by about 15% (ug fatty acid per gram wet brain) indicating brain edema. This decrease did not occur with administration of n-3 emulsions indicating that these n-3 fatty acids prevented the brain edema as well as infarction.
- ROS reactive oxygen species
- Sections of the brain are stained (including both involved and non-involved hemispheres) with antibodies recognizing activated proteins known to participate in neuronal apoptosis (caspase 3, Jun N-terminal kinases), neuronal survival (activated Akt, phosphorylated BAD, FKHR) or to mediate the effects of NMDA-R signaling (CAM KII, and protein kinase C isoforms, in particular PKC ⁇ and PKC ⁇ ). Sections are co-stained with antibodies recognizing neuronal specific proteins (Tau), astrocytes (GFAP) or microglia.
- activated proteins known to participate in neuronal apoptosis caspase 3, Jun N-terminal kinases
- neuronal survival activated Akt, phosphorylated BAD, FKHR
- CAM KII protein kinase C isoforms, in particular PKC ⁇ and PKC ⁇
- Sections are co-stained with antibodies recognizing neuronal specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 triglyceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.
Description
- This application claims priority to U.S. provisional applications 60/799,677 filed on May 12, 2006 and 60/735,862 filed on Nov. 14, 2005, both of which are herein incorporated in their entirety.
- Cerebral hypoxia-ischemia (stroke) is a major cause of morbidity and mortality through all stages of the life cycle, including for infants born prematurely, for children in intensive care units, and for elderly with cerebral vascular accidents. Infants and children who survive hypoxic-ischemic encephalopathy demonstrate lifelong neurologic handicaps, including cerebral palsy, mental retardation, epilepsy, and learning disabilities. Vannucci, R. C. (2000). “Hypoxic-ischemic encephalopathy,” American Journal of Perinatology 17(3): 113-120.
- Cerebral hypoxia-ischemia commonly occurs in critically ill children, most notably in association with cardiopulmonary arrest. Lipid emulsions are commonly used in pediatric intensive care and are an important source of calories in these critically-ill children. Most commercially available emulsions are formed from soybean oil, which have high concentrations of omega-6 (n-6) fatty acids. Lipid emulsions rich in omega-3 (n-3) fatty acids such as α-linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are derived from fish oils, and are not yet widely available for clinical use. However, omega-3 oils have been shown to have beneficial effects in neurologic diseases such as epilepsy, depression, and behavioral disorders. Most studies support a neuroprotective effect due to dietary administration leading to altered membrane lipid composition. In one study, intravenous α-linolenic acid given before and/or after neurologic insult was protective in two animal models, kainate-induced seizures and global ischemia via four vessel occlusion in adult Sprague-Dawley rats. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M, “Polyunsaturated fatty acids are potent neuroprotectors,” The EMBO Journal, 2000 Apr. 17; 19(8): 1784-93. However, there remains a need for methods to protect the brain and other organs and tissues against damage after an initial ischemic insult. The present invention fulfills this need.
- The present invention provides a method of limiting neurological damage resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection against neurological damage.
- The present invention also provides a method of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection to limit cell death.
- Administration of the omega-3 lipid-based emulsion may be either enteral or parenteral. Methods of the present invention also provide further comprise administering a conventional stroke treatment or preventative medication.
- Omega-3 lipid-based emulsions of the present invention comprise at least 10%, preferably at least 20%, omega-3 oil, by weight. In certain embodiments, the omega-3 oil comprises at least 10%, preferably at least 20%, omega-3 triglyceride and/or omega-3 diglyceride and the fatty acids of the omega 3-triglyceride and/or omega-3 diglyceride comprise at least 40% EPA and/or DHA.
- Omega-3 lipid-based emulsions may be administered at any effective dose, such as a dose of 0.05 g/kg to 4 g/kg, and may be administered any time after a hypoxic-ischemic insult, such as 20 minutes to six hours after the ischemic insult or 0-12 hours after the ischemic insult. Additional later administrations are also contemplated, for example an additional later administration is provided 1-24 hours after the insult.
- The methods of the present invention are useful when ischemia has occurred in the organs selected from the group consisting of brain, lung, heart, kidney and large or small intestine.
- The present invention also provides an omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emusion confers a protective benefit on cells against cell death following a hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 triglyceride and/or diglycerides comprise at least 40% EPA and/or DHA.
- The present invention also provides the use of an omega-3 lipid-based emulsion as described herein to make a medicament to limit neurological damage and/or cell death resulting from hypoxic-ischemia.
-
FIG. 1 provides the results of an experiment where rats were given an omega-3 lipid-based emulsion as a neuroprotective both prior and after 60 minutes of hypoxic-ischemia. -
FIG. 2 provides the results of an experiment where rats were given an omega-3 lipid-based emulsion as a neuroprotective both prior and after 65 minutes of hypoxic-ischemia. -
FIG. 3 shows the neuroprotective effect of omega-3 triglycerides just before hypoxic/ischemic insult on the size of brain infarcts as determined by TTC staining. -
FIG. 4 shows the results of four separate experiments where rats were given an omega-3 lipid-based emulsion after 60 minutes of hypoxic-ischemia. Note that 40% of the treated animals had no brain damage and another 40% had less damage than the mean of control animals as assessed by TTC staining. - Definitions
- As used herein “omega-3 lipid-based emulsion” is an oil-in-water emulsion comprising at least about 10% omega-3 oil (and up to 100% omega-3 oil). Preferably the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil.
- As used herein, “omega-3 oils” means any omega-3 fatty acid, including free omega-3 fatty acids and omega-3 triglycerides and omega-3 diglycerides.
- The term “omega-3 fatty acid” means a polyunsaturated fatty acid wherein one of the carbon-carbon double bonds is between the third and fourth carbon atoms from the distal end of the hydrocarbon side chain of the fatty acid. Examples of “omega-3 fatty acid” include α-linolenic acid (18:3n-3; α-ALA; Δ3,6,9), eicosapentaenoic acid (20:5n-3; EPA; Δ5,8,11,14,17), docosahexaenoic acid (22:6n-3; DHA) and docosapentaenoic acid (22:5n-3; DPA; Δ7,10,13,16,19), wherein EPA and DHA are most preferred. Omega-3 fatty acids having at least 20 carbon atoms are herein called “long chain omega-3 fatty acids.”
- The term “omega-3 triglyceride” or “omega-3 diglyceride” refers to a triglyceride or a diglyceride, respectively, comprising at least one omega-3 fatty acid esterified with a glycerol moiety. As used herein, the term “omega-3 tri/diglyceride” means that omega-3 fatty acid comprises an omega-3 triglyceride and/or a diglyceride or any combination thereof.
- It is now well-established that cerebral hypoxia-ischemia of sufficient duration to deplete high energy reserves in neural cells initiates a cascade of events over the hours to days of reperfusion that culminates in extensive death, both necrotic and apoptotic. These events include the generation of reactive oxygen species and oxidative damage to cells, release of inflammatory mediators and initiation of prolonged inflammatory reactions, and ongoing apoptosis that can continue for weeks to months. This applies to ischemic injury to organs in young, adult and elderly humans.
- As an example, neuronal loss following hypoxia/ischemia is believed to result, at least in part, from elevated glutamate release and excitoxicity. Excess glutamate activation of N-methyl-D-aspartic acid (NMDA) receptors induces pro-apoptotic pathways and inhibits anti-apoptotic signaling pathways. Omega-3 fatty acids can modify a number of signaling pathways to effect transcriptional regulation. Not being bound by theory, since prior studies by the present inventors have shown that brain fatty acid profiles are not modified following administration of omega-3 triglyceride emulsions, it is believed that the omega-3 fatty acids protect neurons by modulating signaling pathways that counter the effects of hyper stimulated NMDA receptors, protection against free radical generation and consequent oxidative damage, and thereby prevent/reduce post-ischemic inflammation and release of inflammatory mediators.
- Recent evidence also indicates that routes for blood clearance and tissue uptake of fish oil omega triglycerides are very different from those of omega-6 soy oil long chain triaglycerols (LCT). For example, removal of omega-3 very long chain triaglycerol (VLCT) emulsions from blood seems to depend far less on intravascular lipolysis than does LCT emulsions. While substantial amounts of both emulsions are delivered to tissues as intact triglyceride, this pathway is likely more important for omega-3 triglyceride particles. Omega-3 triglyceride particles, VLCT, are less dependent on “classical” lipoprotein receptor related clearance pathways, than are LCT. Fatty acid derived from omega-3 triglyceride appear to act as stronger inhibitors than LCT in sterol regulatory element (SRE) dependent gene expression-genes that are involved in both triglyceride and cholesterol synthesis.
- The present invention provides methods of limiting or preventing cell death and cell/tissue damage resulting from hypoxic-ischemia. “Limiting” as used herein includes decreasing and/or preventing. The methods of present invention comprise administering an omega-3 lipid-based emulsion of the present invention after an hypoxic-ischemia insult. The present invention also provides, in those cases where the hypoxic-ischemic insult can be predicted, methods of limiting or preventing cell death and cell/tissue damage comprising administering an omega-3 lipid-based emulsion of the present invention before the hypoxic-ischemia insult.
- When the hypoxic-ischemic insult is cerebral, the present invention limits neural cell death and/or limits neurological damage. Since the basic mechanisms of cell death following ischemia after an hypoxic-ischemic insult are similar in most bodily organs, the present invention also provides limiting cell death in other organs such as the heart, large and small intestines, kidney and lung following an hypoxic-ischemia insult. For example, after a colonic ischemic event due to acute mesenteric artery ischemia, chronic mesenteric artery ischemia or ischemia due to mesenteric venous thrombosis, the present invention provides a method of limiting intestinal cell death. Similar prevention of cell death would apply to myocardial infarction.
- Prior studies have shown that omega-6 fatty acids such as omega-6 linoleic acids are far less effective in neuroprotection and cardiac protection when provided before an ischemic event. The studies involved the administration of Intralipid®, a soy oil based emulsion containing 55% of its fatty acids as omega-6 linoleic acid, with a very low content of EPA and DHA (˜2%). Further, direct injection of free fatty acids, as compared to triglycerides or diglycerides, can have serious side effects, such as encephalopathy.
- Accordingly, the methods of the present invention comprise administering an omega-3 lipid-based emulsion comprising at least 10%, preferably at least 20% (up to 100%) by weight of omega-3 oil. Preferably the omega-3 oil comprises at least 10%, preferably at least 20% (up to 100%) omega-3 tri/diglycerides. The fatty acids in the omega-3 tri/diglycerides preferably comprise at least 40% (up to 100%) EPA and/or DHA.
- Sources of omega-3 fatty acids may be from any suitable source such as from fish oils, other oils or may even be synthesized. Although EPA and DHA are preferred omega-3 fatty acids, other omega-3 fatty acids may be used.
- Methods of the present invention preferably comprise administering omega-3 lipid-based emulsions of the present invention either enterally (for example, orogastric or nasogastric) or parenterally (for example, subcutaneous, intravenous, intramuscular, intraperitoneal). Most preferably the emulsion is administered intravenously.
- Omega-3 lipid-based emulsions of the present invention are preferably provided at a dose capable of providing a protective benefit. Those skilled in the art would be able to determine the appropriate dose based on the experimental data presented herein. However, for example a suitable effective and tolerable dose for a human would be about 0.05 g/kg to about 4.0 g/kg. Higher doses may be given as necessary.
- Omega-3 lipid-based emulsions of the present invention are preferably administered parenterally and/or enterally after the ischemic insult (or in some embodiments, before the insult when it can be predicted). The emulsion may be administered to prevent/reduce tissue damage after cerebral hypoxia or stroke as well as hypoxic-ischemic insults in other organs such as heart, kidney, lung, etc. Preferably an omega-3 lipid-based emulsion is administered as soon as possible after the insult (or before in cases where the insult can be predicted) to provide a greater limitation of cell death. For example, in a preferred embodiment an omega-3 lipid-based emulsion is administered from 0-12 hours after the insult. Ideally the administration occurs anywhere from 20 minutes to 6 hours after the insult. Most preferably the emulsion is administered 0-2 hours after the insult. The present invention also provides for multiple administrations of the omega-3 lipid-based emulsion. For example, the emulsion may be first administered within 20 minutes of the insult, followed by a second administration 1-24 hours after the insult. The present invention also contemplates multiple administration(s) of omega-3 lipid-based emulsions following the insult.
- In another embodiment of the invention, methods of limiting or preventing cell death and cell/tissue damage resulting from hypoxic-ischemia further comprise administering an omega-3 lipid-based emulsion of the present in conjunction with standard available therapies (such as surgery and angioplasty) and/or medications given to prevent or treat hypoxia-ischemia. For example, the following drugs are often administered to prevent or treat strokes: antiplatelet medications such as aspirin, clopidogrel, dipyridamole, ticlopidine; anticoagulants such as heparin and warfarin; and thrombolytic agents such as tissue plasminogen activator.
- Preparation of lipid-based emulsions suitable for intravenous delivery are known in the art. Omega-3 lipid-based emulsions according to the invention may be oil-in-water (o/w) emulsions in which the outer continuous phase consists of distilled water purified or sterilized for parenteral purposes. Such oil-in-water emulsions may be obtained by standard methods, i.e. by mixing the oil components followed by emulsification and sterilization. The pH value of the lipid emulsion may be adjusted to a physiologically acceptable value, preferably to a pH of from about 6.0 to about 9.0, more preferably from about 6.5 to about 8.5. Auxiliary agents and additives may be added to the oil mixture prior to emulsification or prior to sterilization.
- Omega-3 lipid-based emulsions according to the invention can be prepared by known standard procedures with inertization. Typically, first the lipids, emulsifier and other auxiliary agents and additives are mixed and then filled up with water with dispersing. The water may optionally contain additional water-soluble components (e.g. glycerol). Preferably omega-3 lipid-based emulsions of the present invention contain lipid particles having a diameter of about 100-400 nanometer, with an average size of 300 nanometers.
- The present invention also provides omega-3 lipid-based emulsions for enteral or parenteral administration to provide a protective benefit on cells against cell death following a hypoxic-ischemic insult. Omega-3 lipid-based emulsions of the present invention comprise at least 10%, preferably at least 20% (up to 100%) by weight of omega-3 oil. Preferably the omega-3 oil comprises at least 10%, preferably at least 20% (up to 100%) omega-3 tri/diglyceride. Fatty acids in the omega-3 tri/diglyceride preferably comprise at least 40% (up to 100%) EPA and/or DHA. The omega-3 lipid-based emulsion preferably comprises 10% to 100% omega-3 tri/diglyceride. In a preferred embodiment, the omega-3 tri/diglyceride contains at least 40% (up to 100%) of their fatty acids as EPA and/or DHA. Preferably, omega-3 emulsions of the present invention are sterile and have a particle size that is preferably between 100-400 nanometer mean diameter, with an average size of 300 nm.
- Postnatal day 19-21 Wistar rats of both genders were subjected to unilateral (right) carotid artery ligation. See Rice, J. E., 3rd, R. C. Vannucci, et al. (1981), “The influence of immaturity on hypoxic-ischemic brain damage in the rat,” Ann Neurol 9(2): 131-41 and Vannucci, S. J., L. B. Seaman, et al. (1996), “Effects of hypoxia-ischemia on GLUT1 and GLUT3 glucose transporters in immature rat brain,” Journal of Cerebral Blood Flow & Metabolism 16(1): 77-81.
- Immediately after ligation, six rats were given 50
mg 20% omega-3 lipid-based emulsion (0.25 cc)(a 20% long chain omega-3 triglyceride-based formula having >45% of total omega-3 fatty acid as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) via orogastric feeding tube, and six control rats were given 0.25 cc water, both enterally. The 20% omega-3 lipid-based emulsion was made placing 20 gm of omega-3 triglyceride in 100 ml of water, and emulsifying with 1.2 gm of egg yolk lecithin. Rats were allowed to recover for 2 hours, then they underwent hypoxia-ischemia for 60 minutes of 8% oxygen at a constant temperature. The six pre-treated rats were given another dose of 50 mg omega-3 lipid-based emulsion immediately after the hypoxia-ischemia and control rats were given another 0.25 cc water. All rats were euthanized at 72 hours of reperfusion. The brains were removed and cut into 2 mm sections and stained with 2,3,5,Triphenyl-2H-tetrazolium chloride (TTC). TTC is a vital die that stains cells red that have respiring mitochondria. Dead tissue (infarct) appears white. The sections were scored as follows: - 0—no evidence of edema or cell death
- 1—edema without cell death
- 2—edema with minimal cell death
- 3—edema with significant cell death
- All rats survived 60 minutes of hypoxia-ischemia. Six of the six control rats had edema and/or cell death with a mean score of 2+/−0.83 (standard deviation), while two of the six treated rats had damage with a mean score of 0.42+/−0.62 (p<0.005) See
FIG. 1 . - Postnatal day 19-21 Wistar rats of both genders were subjected to unilateral (right) carotid artery ligation. Immediately after ligation, six rats were given 50
mg 20% omega-3 lipid-based emulsion (0.25 cc)(20% omega-3 fatty acid based formula having ≧40% of total omega-3 fatty acid as EPA and DHA)) via orogastric feeding tube and six control rats were given 0.25 cc water, both enterally. The emulsion was made as described in Example 1. The rats recovered for two hours, and then underwent hypoxia-ischemia for 65 minutes of 8% oxygen at a constant temperature. The six pre-treated rats were given another dose of 50 mg omega-3 lipid-based emulsion immediately after the hypoxia-ischemia and control rats were given another 0.25 cc water. All rats were euthanized at 72 hours of reperfusion. The brains were removed and cut into 2 mm sections and stained with 2,3,5,Triphenyl-2H-tetrazolium chloride (TTC). The sections were scored as follows: - 0—no evidence of edema or cell death
- 1—edema without cell death
- 2—edema with minimal cell death
- 3—edema with significant cell death
- The 65 minutes of hypoxia-ischemia produced damage in all rats. Four of the six control rats survived with a mean score of 2.75+/−0.50, while five of the six treated rats survived with a mean score of 1.70+/=0.76 (p<0.05). See
FIG. 2 . - Postnatal day 19-21 Wistar rats were subjected to unilateral (right) carotid artery. Immediately after ligation, six rats were given 50 mg of a 20% omega-3 lipid-based emulsion (0.25 cc), and six control rats were given 0.25 cc water, both enterally. The emulsion was as described above in Example 1. Rats were allowed to recover for two hours, then underwent hypoxia-ischemia for 60 minutes of 8% oxygen at a constant temperature. The six pre-treated rats were given another dose of 50 mg omega-3 triglyceride lipid emulsion immediately after the hypoxia/ischemia and control rats were given another 0.25 cc water. At 72 hours of reperfusion, the rats were euthanized and their brains removed, cut into 2 mm sections and stained with 2,3,5triphenyl-2H-tetrazolium chloride (TTC). The damage in each animal was then given a score from 0 (no damage) to 4 (>60% ipsilateral hemisphere infarcted). All of the vehicle-treated animals suffered brain damage, with a mean damage score of 2.00+0.89; the omega-3 triglyceride lipid emulsion-treated rats were significantly less damaged, having a mean damage score 0.33+0.52, p<0.05. See
FIG. 3 showing the effect of administration of omega-3 triglycerides just before hypoxic-ischemic insult on the size of brain infarcts (as determined by TTC staining). Coronal sections were shown of tracings of infarcted area from anterior (top) and midsections (bottom) of brain in representative control and omega triglyceride treated rats. - These results show that when omega-3 triglycerides were administered either immediately before and/or after hypoxia-ischemia they confer a significant neuroprotection. Very similar results were obtained when the omega-3 triglycerides were injected parenterally.
- Postnatal day 19-21 rat pups were subjected to unilateral carotid artery ligation and 60 minutes of hypoxic ischemia, according to the previously described protocol. On four separate occasions, rats were treated by parenteral injection of omega-3 lipid-based emulsion (100 mg) immediately after the insult, and again at four hours after the insult. The emulsion was as described above in Example 1. Brain damage was evaluated by TTC staining at 72 hours of reperfusion. In each instance, administration of the omega-3 lipid-based oil emulsion provided greater than 50% protection, i.e. reduction of tissue damage.
-
FIG. 4 shows the results of these experiments.FIG. 4 represents at total of 14 control subjects (saline-treated) and 21 treated subjects (omega-3 lipid-based emulsion treated). Mean damage scores were: 1.93±0.22 (SEM), control, 0.78±0.16 emulsion-treated; p<0.0001 by two-tailed test. The data inFIG. 4 is presented as a scatter plot. Thus, in addition to the significance of the overall protection, it can be seen that 40% of the treated animals were 100% protected (no damage at all, compared to 1/14 untreated; 40% suffered only mild damage, compared to 1/14 mildly damaged untreated animals. These results indicate that treatment following hypoxic-ischemia provides a neuroprotective benefit as indicated by a reduction of tissue damage. - Preliminary experiments conducted in the adult mouse show a comparable level of neuroprotection from hypoxic-ischemic damage.
- Fatty acyl composition analyses of brain lipids (by gas liquid chromatography) after hypoxia/ischemia show no relative differences between infarcted brain versus non infarcted brain indicating that effects of acute administration of n-3 emulsions are not dependent on fatty acid compositional changes in brain membranes. In the infarcted areas, however, absolute concentrations of all fatty acids fell to similar degrees by about 15% (ug fatty acid per gram wet brain) indicating brain edema. This decrease did not occur with administration of n-3 emulsions indicating that these n-3 fatty acids prevented the brain edema as well as infarction.
- Studies on the effects of omega-3 triglyceride treatment on the generation of reactive oxygen species (ROS) and markers of oxidative damage, as well as indices of inflammation at 2, 4, 8 and 24 h after the hypoxic/ischemic insult are performed. Lasting protection is confirmed by brain histopathology at eight weeks following the original hypoxia-ischemic. Sections of the brain are stained (including both involved and non-involved hemispheres) with antibodies recognizing activated proteins known to participate in neuronal apoptosis (
caspase 3, Jun N-terminal kinases), neuronal survival (activated Akt, phosphorylated BAD, FKHR) or to mediate the effects of NMDA-R signaling (CAM KII, and protein kinase C isoforms, in particular PKCγ and PKCζ). Sections are co-stained with antibodies recognizing neuronal specific proteins (Tau), astrocytes (GFAP) or microglia. These analyses allow quantification of the effect of omega-3 triglycerides on hypoxia-ischemia induced changes in apoptotic versus anti-apoptotic signaling in neurons, as well as gain indices of astrocytic or microglia involvement. Further, whole brain extracts from involved and non-involved hemispheres are prepared to quantify the extent of caspase, JNK and Akt activation by immunoblotting. These extracts are also used to address the question of whether omega-3 triglycerides treatment effects the activation of brain sterol regulatory element binding proteins (SREBP) in vivo.
Claims (21)
1. An omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emulsion confers a protective benefit on cells against cell death following an hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight.
2. The composition of claim 1 , wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride.
3. The composition of claim 3 , wherein the omega-3 triglyceride and/or diglyceride comprises at least 40% EPA and/or DHA fatty acids.
4. An omega-3 lipid-based emulsion suitable for enteral or parenteral administration, wherein said emulsion confers a protective benefit on cells against cell death following an hypoxic-ischemic insult, said emulsion comprising at least 20% omega-3 oil, by weight, wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride and wherein the omega-3 triglyceride and/or diglyceride comprises at least 40% EPA and/or DHA fatty acids
5. A method of limiting neurological damage resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection against neurological damage.
6. A method of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a cerebral hypoxic-ischemia insult wherein the omega-3 lipid-based emulsion comprises omega-3 oil effective to confer protection to limit cell death.
7. The method of claim 5 or 6 wherein the administration is either enteral or parenteral.
8. The method of claim 5 or 6 further comprising administering a conventional stroke treatment or preventative medication.
9. The method of claim 6 wherein the omega-3 lipid-based emulsion comprises at least 10% omega-3 oil, by weight.
10. The method of claim 6 wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight.
11. The method of claim 6 wherein the omega-3 oil comprises at least 10% omega-3 triglyceride and/or omega-3 diglyceride.
12. The method of claim 11 wherein the omega-3 triglyceride and/or omega-3 diglyceride comprise at least 40% EPA and/or DHA fatty acids.
13. The method of claim 6 wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride, and wherein the omega-3 triglyceride and/or diglyceride comprise at least 40% EPA and/or DHA fatty acids.
14. The method of claim 13 wherein the omega-3 lipid-based emulsion is administered at a dose of 0.05 g/kg to 4 g/kg.
15. The method of claim 6 wherein the omega-3 lipid-based emulsion is administered at 20 minutes to six hours after the hypoxic-ischemic insult.
16. The method of claim 6 wherein the omega-3 lipid-based formula is administered is 0-12 hours after the hypoxic-ischemic insult.
17. The method of claim 6 wherein the administration is followed by a later administration of the omega-3 lipid-based emulsion.
18. The method of claim 17 wherein the later administration is provided 1-24 hours after the hypoxic-ischemic insult.
19. The method of claim 18 wherein the later administration is provided 4 hours after the hypoxic-ischemic insult.
20. The method of claim 6 , wherein the ischemia has occurred in the organs selected from the group consisting of brain, lung, heart, kidney and large or small intestine.
21. The method of claim 5 wherein the omega-3 lipid-based emulsion comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglyceride and/or diglyceride, and wherein the omega-3 triglyceride and/or diglyceride comprise at least 40% EPA and/or DHA fatty acids.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/558,568 US20070149617A1 (en) | 2005-11-14 | 2006-11-10 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
US13/336,290 US9084801B2 (en) | 2005-11-14 | 2011-12-23 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
US14/738,822 US20150272921A1 (en) | 2005-11-14 | 2015-06-12 | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73586205P | 2005-11-14 | 2005-11-14 | |
US79967706P | 2006-05-12 | 2006-05-12 | |
US11/558,568 US20070149617A1 (en) | 2005-11-14 | 2006-11-10 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,290 Division US9084801B2 (en) | 2005-11-14 | 2011-12-23 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070149617A1 true US20070149617A1 (en) | 2007-06-28 |
Family
ID=37882443
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/558,568 Abandoned US20070149617A1 (en) | 2005-11-14 | 2006-11-10 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
US13/336,290 Expired - Fee Related US9084801B2 (en) | 2005-11-14 | 2011-12-23 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
US14/738,822 Abandoned US20150272921A1 (en) | 2005-11-14 | 2015-06-12 | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,290 Expired - Fee Related US9084801B2 (en) | 2005-11-14 | 2011-12-23 | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs |
US14/738,822 Abandoned US20150272921A1 (en) | 2005-11-14 | 2015-06-12 | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs |
Country Status (2)
Country | Link |
---|---|
US (3) | US20070149617A1 (en) |
WO (1) | WO2007059431A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100196461A1 (en) * | 2009-01-30 | 2010-08-05 | Simpkins Cuthbert O | Resuscitation fluid |
US20110086914A1 (en) * | 2009-10-13 | 2011-04-14 | Bailes Julian E | Methods for Treating Traumatic Brain Injury |
US20110200645A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Free Fatty Acid Emulsions |
US20110206741A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | DHA Triglyceride Emulsions |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
WO2014072311A1 (en) | 2012-11-07 | 2014-05-15 | Centre Hospitalier Universitaire Vaudois | Medicament comprising at least one omega-3 polyunsaturated fatty acid |
US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
US9387162B2 (en) | 2007-12-22 | 2016-07-12 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries |
CN111182902A (en) * | 2017-09-01 | 2020-05-19 | 黄玲惠 | Adhesive compositions for treating ischemia |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014130746A1 (en) * | 2013-02-20 | 2014-08-28 | The Trustees Of Columbia University In The City Of New York | Use of an omega-3 lipid-based emulsion for protecting human organs from ischemic injury |
US20100197785A1 (en) * | 2007-07-25 | 2010-08-05 | Epax As | Omega-3 fatty acid fortified composition |
WO2013044176A2 (en) * | 2011-09-23 | 2013-03-28 | University Of Southern California | Methods and compositions for the treatment of ischemic stroke |
US10070643B2 (en) | 2013-03-28 | 2018-09-11 | The Trustees Of Columbia University In The City Of New York | Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation |
EP3565538A4 (en) * | 2017-01-08 | 2020-10-28 | RESQ Pharma Inc. | Methods for decreasing injuries associated with intraoperative hypotension |
CA3102464C (en) | 2018-06-05 | 2023-09-05 | Dsm Ip Assets B.V. | Process for the production of diglycerides |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5160759A (en) * | 1989-06-07 | 1992-11-03 | Kao Corporation | Edible oil-in-water emulsion |
US5214062A (en) * | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
US5700837A (en) * | 1994-04-21 | 1997-12-23 | Nestec Ltd. | Method and composition for normalizing injury response |
US6020020A (en) * | 1995-11-24 | 2000-02-01 | Loders-Croklaan B.V. | Composition based on fish oil |
US6306908B1 (en) * | 1997-02-21 | 2001-10-23 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
US6448292B2 (en) * | 2000-03-21 | 2002-09-10 | Kao Corporation | Oil composition |
US20030144356A1 (en) * | 2000-05-25 | 2003-07-31 | Goodale David Buell | Formulation |
US20030149118A1 (en) * | 2000-09-29 | 2003-08-07 | Kraft Foods Holdings, Inc. | Method and composition which inhibits the oxidation of omega-3 and omega-6 polyunsaturated lipids |
US20030175403A1 (en) * | 2002-03-14 | 2003-09-18 | Gurin Michael H. | Potentiated bioactive additives and method of use |
US20070281993A1 (en) * | 2004-03-04 | 2007-12-06 | Geila Rozen | Structured Triglycerides And Emulsions Comprising Same |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005261A1 (en) | 1987-01-16 | 1988-07-28 | Tops Systems, Inc. | Total organ perfusion system |
US4895876A (en) | 1987-03-20 | 1990-01-23 | Air Products And Chemicals, Inc. | Concentrated stable fluorochemical aqueous emulsions containing triglycerides |
US6444432B1 (en) | 1997-06-13 | 2002-09-03 | Alan M. Kleinfeld | Method of detection of cardiac ischemia using fatty acid binding protein |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
AU3843999A (en) * | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
EP1279400A1 (en) * | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
WO2005013908A2 (en) * | 2003-08-05 | 2005-02-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration |
WO2008036353A2 (en) | 2006-09-19 | 2008-03-27 | The Trustees Of Columbia University In The City Of New York | Omega-3 diglyceride emulsions |
US9034389B2 (en) | 2009-03-11 | 2015-05-19 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
WO2011103514A1 (en) | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha triglyceride emulsions |
-
2006
- 2006-11-10 US US11/558,568 patent/US20070149617A1/en not_active Abandoned
- 2006-11-10 WO PCT/US2006/060777 patent/WO2007059431A1/en active Application Filing
-
2011
- 2011-12-23 US US13/336,290 patent/US9084801B2/en not_active Expired - Fee Related
-
2015
- 2015-06-12 US US14/738,822 patent/US20150272921A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5160759A (en) * | 1989-06-07 | 1992-11-03 | Kao Corporation | Edible oil-in-water emulsion |
US5214062A (en) * | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
US5700837A (en) * | 1994-04-21 | 1997-12-23 | Nestec Ltd. | Method and composition for normalizing injury response |
US6020020A (en) * | 1995-11-24 | 2000-02-01 | Loders-Croklaan B.V. | Composition based on fish oil |
US6306908B1 (en) * | 1997-02-21 | 2001-10-23 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
US6448292B2 (en) * | 2000-03-21 | 2002-09-10 | Kao Corporation | Oil composition |
US20030144356A1 (en) * | 2000-05-25 | 2003-07-31 | Goodale David Buell | Formulation |
US20030149118A1 (en) * | 2000-09-29 | 2003-08-07 | Kraft Foods Holdings, Inc. | Method and composition which inhibits the oxidation of omega-3 and omega-6 polyunsaturated lipids |
US20030175403A1 (en) * | 2002-03-14 | 2003-09-18 | Gurin Michael H. | Potentiated bioactive additives and method of use |
US20070281993A1 (en) * | 2004-03-04 | 2007-12-06 | Geila Rozen | Structured Triglycerides And Emulsions Comprising Same |
Non-Patent Citations (2)
Title |
---|
Billman, George, Prevention of Ischemia-induced Ventricular Fibrillation by [omega]3 fatty acids, 1994, Proc. Natl. Acad. Sci. USA, Vol 91, pages 4427-4430. * |
Billman, George, The Effects of Omega-3 Fatty Acids on Ventricular Fibrillation Induced by Myocardial Ischemia, 1994, American Heart Association, Preceedings from the Scientific Conference on Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine (Houston, Texas), April 17-19, 1994, pages 159-165. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
US9387162B2 (en) | 2007-12-22 | 2016-07-12 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries |
US9439855B2 (en) | 2007-12-22 | 2016-09-13 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
US9622968B2 (en) | 2007-12-22 | 2017-04-18 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
US20100196461A1 (en) * | 2009-01-30 | 2010-08-05 | Simpkins Cuthbert O | Resuscitation fluid |
US20110086914A1 (en) * | 2009-10-13 | 2011-04-14 | Bailes Julian E | Methods for Treating Traumatic Brain Injury |
US20110200645A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Free Fatty Acid Emulsions |
US20110206741A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | DHA Triglyceride Emulsions |
WO2014072311A1 (en) | 2012-11-07 | 2014-05-15 | Centre Hospitalier Universitaire Vaudois | Medicament comprising at least one omega-3 polyunsaturated fatty acid |
CN111182902A (en) * | 2017-09-01 | 2020-05-19 | 黄玲惠 | Adhesive compositions for treating ischemia |
JP2020536850A (en) * | 2017-09-01 | 2020-12-17 | エクセル メッド、エルエルシー | Viscous composition for treating ischemia |
Also Published As
Publication number | Publication date |
---|---|
WO2007059431A1 (en) | 2007-05-24 |
US20120095095A1 (en) | 2012-04-19 |
US20150272921A1 (en) | 2015-10-01 |
US9084801B2 (en) | 2015-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9084801B2 (en) | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs | |
Calder et al. | Lipids in the intensive care unit: recommendations from the ESPEN Expert Group | |
US8633253B2 (en) | Omega-3 diglyceride emulsions | |
Wen et al. | DHA-PC and DHA-PS improved Aβ1–40 induced cognitive deficiency uncoupled with an increase in brain DHA in rats | |
KR100657642B1 (en) | Oil comprising eicosapentaenoic acid and/or stearidonic acid | |
DE60132081T2 (en) | PREPARATION FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES | |
KR101331658B1 (en) | Glycerophospholipids containing omega-3 and omega-6 fatty acids | |
Lim et al. | Improved outcome after spinal cord compression injury in mice treated with docosahexaenoic acid | |
RU2625760C2 (en) | Therapeutic application of krill oil | |
KR20070089216A (en) | Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of hiv-infected patients | |
US11744864B2 (en) | Method of treating eye diseases with krill oil | |
ES2189891T5 (en) | EMULSIONS OF OPTIMIZED LIPIDS FOR HYDROLYSIS AND USE OF THE SAME. | |
CN105939705B (en) | Composition comprising triglycerides of EPA and DHA for parenteral administration | |
JP2023521917A (en) | Stable diglyceride emulsions and methods for treating organ damage | |
US20140287004A1 (en) | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs | |
JPH06172169A (en) | Therapy by using fatty acid | |
WO2014130746A1 (en) | Use of an omega-3 lipid-based emulsion for protecting human organs from ischemic injury | |
Guthrie et al. | Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates. Nutrients 2021, 13, 508 | |
Yurko-Mauro | Memory improvement with docosahexaenoic acid Study (MIDAS)-brief review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DECKELBAUM, RICHARD J.;VANNUCCI, SUSAN J.;REEL/FRAME:018963/0021 Effective date: 20070226 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |